טוען...
The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer
BACKGROUND: Gemcitabine is proven to be the first-line standard treatment of breast cancers. Yet, little is known involving gemcitabine resistance and remains largely to be elucidated. MATERIALS AND METHODS: We evaluated the expression of Cx43 in gemcitabine-resistant cells and parental cells by qua...
שמור ב:
| הוצא לאור ב: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6790128/ https://ncbi.nlm.nih.gov/pubmed/31632081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S218524 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|